French homecare device industry demands eleventh hour hearing
This article was originally published in Clinica
There is a sense of urgency at Appamed, the French association that represents manufacturers of home healthcare products. It is pushing for a hearing with the authorities that decide on the reimbursement listing and pricing on medical devices, to try and ensure they are better informed before making the next wave of expected pricing cuts.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.